- Home
- INSM vs FUTU Comparison
INSM vs FUTU Comparison
Compare INSM & FUTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- FUTU
- Stock Information
- Founded
- INSM 1988
- FUTU 2011
- Country
- INSM United States
- FUTU Hong Kong
- Employees
- INSM N/A
- FUTU N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- FUTU Investment Bankers/Brokers/Service
- Sector
- INSM Health Care
- FUTU Finance
- Exchange
- INSM Nasdaq
- FUTU Nasdaq
- Market Cap
- INSM 29.0B
- FUTU 26.1B
- IPO Year
- INSM 2000
- FUTU 2019
- Fundamental
- Price
- INSM $189.60
- FUTU $199.04
- Analyst Decision
- INSM Strong Buy
- FUTU Strong Buy
- Analyst Count
- INSM 19
- FUTU 5
- Target Price
- INSM $171.12
- FUTU $205.60
- AVG Volume (30 Days)
- INSM 2.1M
- FUTU 2.5M
- Earning Date
- INSM 10-30-2025
- FUTU 11-18-2025
- Dividend Yield
- INSM N/A
- FUTU 0.98%
- EPS Growth
- INSM N/A
- FUTU 86.80
- EPS
- INSM N/A
- FUTU 7.17
- Revenue
- INSM $447,022,000.00
- FUTU $2,051,001,847.00
- Revenue This Year
- INSM $32.08
- FUTU $65.08
- Revenue Next Year
- INSM $125.86
- FUTU $11.67
- P/E Ratio
- INSM N/A
- FUTU $27.74
- Revenue Growth
- INSM 30.34
- FUTU 69.56
- 52 Week Low
- INSM $60.40
- FUTU $70.60
- 52 Week High
- INSM $197.08
- FUTU $201.50
- Technical
- Relative Strength Index (RSI)
- INSM 76.69
- FUTU 65.28
- Support Level
- INSM $154.79
- FUTU $188.52
- Resistance Level
- INSM $168.22
- FUTU $200.00
- Average True Range (ATR)
- INSM 6.44
- FUTU 8.00
- MACD
- INSM 1.81
- FUTU 3.86
- Stochastic Oscillator
- INSM 82.31
- FUTU 94.87
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.